Familial hypertrophic cardiomyopathy (FHC) is caused by mutations in genes encoding sarcomeric proteins. Incomplete penetrance suggests the existence of modifier genes. Calmodulin (CaM) could be of importance given the key role of Ca 2þ for cardiac contractile function and growth. Any variant that affects CaM expression and/or function may impact on FHC clinical expression.
Introduction
Hypertrophic cardiomyopathy is defined by the presence of increased ventricular wall thickness or mass in the absence of loading conditions (hypertension, valve disease) sufficient to cause the observed abnormality. 1 More than 70% of cases are familial (Familial hypertrophic cardiomyopathy-FHC). The major features of the disease are asymmetric left ventricular hypertrophy (LVH), myocyte disarray, and interstitial myocardial fibrosis. 2, 3 The pure form of FHC is inherited in an autosomal dominant pattern and is associated with mutations in at least 13 genes encoding sarcomeric proteins (for review, see reference 4). Out of them, MYBPC3 5, 6 and MYH7 7 encoding cardiac myosin-binding protein C (cMyBP-C) or b-myosin heavy chain, respectively, are the most frequently mutated genes. 8 One of the major features of FHC is a wide phenotypic heterogeneity among affected subjects, which is characterized by variable degree or distribution of hypertrophy and prognosis. Part of this can be explained by locus heterogeneity. 4,9 -12 Moreover, genetic studies have revealed the presence of clinically healthy individuals carrying the mutant allele, which is, in first-degree relatives, associated with a typical phenotype of the disease. 13, 14 This variable expressivity suggests the existence of modifier genes or polymorphisms, which modulate the phenotypic expression of the disease. Obvious candidate modifier genes encode proteins implicated in cardiac growth and hypertrophy. Several components of the renin -angiotensin-aldosterone system (RAAS) have been analysed in patients with FHC. 15 An association has been found between the D allele of the angiotensin I-converting enzyme (ACE) polymorphism and cardiac hypertrophy in FHC patients carrying an MYH7 R403 codon mutation. 16 The AT1 receptor A.C1166 and AT2 receptor A.C3123 polymorphisms contribute to cardiac hypertrophy in specific groups of patients with FHC. 17, 18 Finally, several genetic polymorphisms of the RAAS influence penetrance and degree of cardiac hypertrophy in gene carriers from one family with FHC caused by an MYBPC3 mutation. 19 Proteins involved in hypertrophic pathways or mediators of Ca 2þ signalling in cardiomyocytes are promising candidates as modifier genes. 20, 21 Many of the actions of Ca 2þ are mediated through its interaction with calmodulin (CaM), which serves as an intracellular sensor for Ca 2þ ions and plays a major role in Ca 2þ homeostasis. Thus, any genetic variants that directly affect CaM gene expression and/or function would be expected to impact on the intracellular Ca 2þ concentration. In humans, CaM is encoded by a multigene family consisting of three members, CALM1, CALM2, and CALM3, which are located on chromosomes 14q24-q31, 2p21.1-p21.3, and 19q13.2-q13.3. 22 In the present study, we screened for mutations in the promoter region of the human CaM III gene (CALM3), identified a new T.A polymorphism at position 234 (234T.A), which was differently distributed between FHC patients and controls and between affected and healthy carriers of an FHC mutation. Moreover, we found that the CALM3 promoter activity varied with the polymorphism in both HEK293 cells and neonatal rat cardiac myocytes (NRCMs). We provide evidence that the new 234T.A CALM3 polymorphism is a potential modifier gene for FHC in patients carrying a mutation in either the MYH7 or MYBPC3 gene.
Methods
The EUROGENE Heart Failure Project is a European consortium aimed at the evaluation of genetic factors in familial and sporadic forms of dilated and hypertrophic cardiomyopathies.
Patients
After informed consent was obtained by applying the guidelines of the Comité d'Ethique du Centre Hospitalier Universitaire de la Pitié Salpêtrière (Paris), all subjects underwent clinical and cardiovascular examination including a 12-lead electrocardiogram (ECG) and M-mode, two dimensional, and Doppler echocardiography at the time of genotyping. The diagnosis of FHC was based on ECG and echocardiography as described previously 8 ; briefly, major echo diagnostic criteria were defined by a left ventricular end-diastolic maximal wall thickness (LVWT) .15 mm for index cases; for relatives, an LVWT .13 mm or the presence of major ECG abnormalities (LVH assessed by a Romhilt -Estes score !4 and/or Q waves .0.04 s or .1/3 R wave and/or significant ST-T changes). Left ventricular enddiastolic maximal wall thickness measurements were obtained at different locations (anterior and posterior septum, lateral and posterior wall) from the parasternal short-axis view, at both the mitral valve and papillary muscle levels, and at the parasternal long-axis view. Consecutive patients who fulfilled the inclusion criteria were screened to participate in the study from different tertiary centres in Europe (see Appendix). It could be a patient referred for the first time, a patient with a known diagnosis of FHC during a routine follow-up, or a relative screened through a familial survey. Control individuals (134, 72% spouses of the probands and 28% individuals without cardiac diseases), FHC index cases (180), and relatives (249) recruited from the EURO-GENE Heart Failure cohort were included in the study (Figure 1) . Familial hypertrophic cardiomyopathy relatives were divided into two groups. The first was composed of affected carriers (112 individuals). The second was composed of healthy carriers (137 individuals). All individuals were Caucasian, and the age did not differ between index cases and controls and between affected and healthy carriers ( Table 1) . Both index cases and relatives were screened for mutations for the major FHC disease genes, and only those carrying a mutation in MYH7 or MYBPC3 genes were included in this study ( Figure 1 ). Seven index cases and 8 relatives carry two mutations (13 compound heterozygotes, 2 homozygotes).
Genetic analyses
Genomic DNA was extracted from blood samples as described. 23 The promoter region of the human CALM3 gene was determined on the basis of the genomic sequence (Genbank accession number Figure 1 Distribution and numbers of the individuals enrolled in the study. FHC, patients carrying a familial hypertrophic cardiomyopathy mutation; C3, patients carrying a mutation in MYBPC3; M7, patients carrying a mutation in MYH7.
Polymorphism in human calmodulin III gene promoter X52606). 24 Amplification was performed using the following primers: CALM3 F-5 0 -GCGGCGAGGGAAAGTAGTC-3 0 and CALM3 R-5 0 -GCGTCCGCGCCTCCACACT-3 0 on genomic DNA in a standard cycling programme composed of 36 cycles of 30 s at 948C, 30 s at 608C, and 30 s at 728C, with the GC-Rich PCR-System (Roche Diagnostics). The 279 bp polymerase chain reaction (PCR) fragment was then analysed by single-strand conformation polymorphism (SSCP): it was heat-denaturated for 5 min in a formamide buffer at 958C, kept on ice, loaded onto a 10% polyacrylamide gel, and then run at 8 mA per gel at 78C and 208C in the Mighty Small Gel Electrophoresis Unit (Hoeffer). The bands were visualized after silver staining of the gels (Pharmacia). Polymerase chain reaction products were sequenced using the dGTP BigDyeTM Terminator (Applied Biosystems). The reaction products were then electrophoresed on an automated laser fluorescent DNA sequencer 377 (Applied Biosystems). Some of the individuals were screened for the SNP on the MassAR-RAY w system (Sequenom) applying the iPLEX w method and MALDI-TOF mass spectrometry for analyte detection. The reactions were performed according to the standard protocol recommended by the supplier. Primers used were F-5 0 -GCGGCGAGGGAAAGTAGTC-3 0 and R-5 0 -CGCAGGCGCGGAGGTGTGA-3 0 .
Plasmid constructs
The pGL 2 B vector containing the 1129 bp 5 0 -flanking sequence of the human CALM3 gene carrying the T allele (pGL 2 B-CAM3-T) was kindly provided by Emmanuel Strehler (Rochester, MI, USA). 25 The T.A variant was introduced into the pGL 2 B-CAM3-T vector using the QuickChange TM site-directed mutagenesis kit (Stratagene) according to the manufacturer's instructions using the following primers:
0 . The resulting plasmid was named pGL 2 B-CAM3-A.
Transfection in HEK293 cells and neonatal rat cardiomyocytes
HEK293 cells were plated at a density of 8 Â 10 5 cells in six-well plates.
After 24 h, culture medium was changed to DMEM Glutamax (Gibco) without serum or penicillin/streptomycin (P/S). Transfection was performed using Fugene HD transfection reagent (Roche Diagnostics) and performed according to manufacturer's instructions using 4 mL Fugene transfection reagent. Transfection efficiency was determined with 0.2 mg pRLTK (Renilla luciferase). Negative control was performed using a plasmid without any promoter [pGL2-B (2), 1.4 mg] and positive control using a plasmid containing a minimal SV40 promoter [pGL2-C (þ), 1.5 mg]. For both pGL 2 B-CAM3-T and pGL2B-CAM3-A, 1.8 mg plasmid was used. Medium was changed 5 h after transfection to DMEM with 10% FCS and 1% P/S, and cells were incubated for further 24 h, then rinsed once with 1Â PBS and lysed in 250 mL lysis buffer. Cell lysates were subjected to three thaw/freeze cycles, and stored at 2808C or at once processed for luciferase assays. For luciferase assays, 20 mL of cell lysates were processed using the Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer's protocol in a luminometer. The results were expressed as a ratio of the activities of Firefly (pGL2-C) to Renilla luciferase (pRLTK). Neonatal rat cardiac myoyctes were prepared using the Worthington Neonatal Cardiomyocyte Isolation System (Worthington Biochemical Corporation) from 12 hearts from 1 -3-day-old rats. Cells were plated at a density of 1 Â 10 6 cells in 1% gelatine-coated six-well plates. The cells were incubated in a humidified 5% CO 2 atmosphere at 378C for 5 days. Transfections were performed after 48 h culture using the CaPO 4 method as described previously. 26, 27 The total amount of DNA was 20 mg. Nine micrograms of pGL 2 B-CAM3-T or pGL 2 B-CAM3-A plasmids were added. Then, 7 mg pGL2-B (2) for the negative control and 7.6 mg pGL2-C (þ) for the positive control were applied. After 6 h of incubation, cells were washed twice and incubated for 20 min in MEM, 5% FCS, 1% P/S, 30 mM Hepes, pH 7.5. Then, cells were washed twice, and medium was changed to MEM, 5% FCS, 1% P/S, and incubated overnight. Cell lysis and luciferase assays were performed as described earlier.
Statistical analysis
Patients' age and the promoter activity were expressed as mean + SD.
Comparison was performed using an unpaired Student's t-test. The distribution of CALM3 genotypes between control individuals and FHC index patients were done with Fisher's exact test. The generalized estimating equation model was used to assess whether there was an association between CALM3 genotypes (AA, AT, or TT, respectively) and index cases, healthy and affected carriers, respectively. Individuals were nested under their families to account for the clustering of the patients. The familial correlation was modelled assuming independent correlation for the working correlation matrix; a cumulative logit link with multinomial distribution was applied with a type 3 analysis (SAS PROC GENMOD, REPEATED option). Generalized estimating equations are a standard approach to the analysis of correlated data such as family data and can be intuitively thought of as similar to proportional odds logistic regression models in this case, except that they account for the correlation among pedigrees. The Bonferroni-Holm procedure was applied to account for the inflation of type I error due to multiple comparisons. P-values were adjusted for multiplicity for each of the two samples separately (FHC and controls, and cell cultures); P , 0.05 was considered significant. All tests performed were two-sided. Statistical analyses were performed using SAS 9.1.3 (Cary, NC, USA).
Results
Identification of a 234T>A polymorphism in human CALM3 gene A total of 134 control individuals were studied. A PCR fragment of the human CALM3 promoter region was analysed by SSCP sequencing or MALDI-TOF mass spectrometry ( Figure 2) . This shows three different patterns in the control population by SSCP ( Figure 2B ) and MALDI-TOF ( Figure 2D) . Sequence analysis revealed a T.A polymorphism at position 234 of the human CALM3 gene (234T.A), which gave rise to three different genotypes, TT, AT, and AA ( Figure 2C ). 
Association of the 234T>A CALM3 gene polymorphism with hypertrophic cardiomyopathy
A total of 180 unrelated FHC index cases with a known diseasecausing mutation (data not shown) were analysed. The frequency of T allele was significantly higher in FHC patients when compared with controls (0.85 vs. 0.70, P , 0.0001, data not shown). Table 2 shows that the distribution of CALM3 genotypes significantly differed in FHC patients when compared with controls (P ¼ 0.0005) with a higher frequency of TT genotypes (0.73 vs. 0.51) and a lower frequency of both AT (0.24 vs. 0.37) and AA genotypes (0.03 vs. 0.11). By separating FHC patients in two subgroups, Polymorphism in human calmodulin III gene promoter one carrying an MYBPC3 mutation and the other an MYH7 mutation, similar results were observed (P ¼ 0.0063). All patients' relatives carrying a mutation in MYBPC3 or MYH7 were then analysed and divided into two groups. The first was composed of clinically affected carriers (112 individuals). The second was composed of clinically healthy carriers (137 individuals). The age did not differ between the two groups ( Table 1) . Affected carriers had a 0.56 times higher odds of carrying a T allele compared with healthy carriers, although this finding was not significant (P ¼ 0.053, Table 3 ). In contrast, the odds for carrying a T allele were not different between index cases and either affected or healthy carriers ( Table 4) .
CALM3 promoter activity is modulated by the 234T>A polymorphism
We then investigated whether the 234T.A polymorphism impacts on CALM3 promoter activity after the transfection of HEK293 cells and NRCM with pGL2-luciferase reporter vectors containing either CALM3-T or CALM3-A promoters (Figure 3) . In both cell types, the vector containing the CALM3-T promoter activity gave rise to at least four-fold higher luciferase activity than the positive control consisting of the minimal SV40 promotor, indicating that the 5 0 flanking region of the CALM3 gene refers significant promotor activity as shown previously in another cell type. 25 Importantly, the CALM3-T promoter activity was only 43 and 72% of that of the CALM3-A activity in HEK293 cells (1.00 + 0.19 vs. 2.31 + 0.13, P ¼ 0.00001) and in NRCM (0.96 + 0.10 vs. 1.33 + 0.08, P ¼ 0.00727), respectively.
Discussion
In the present study, we describe a new 234T.A polymorphism in the 5 0 -flanking region of human CALM3 gene, show that the distribution of the CALM3 genotypes varied between FHC patients and controls, and provide evidence that CALM3 promoter activity depends on the polymorphism in both HEK293 cells and NRCM.
The distribution of CALM3 genotypes in FHC patients was significantly different when compared with control individuals and did not depend on the underlying FHC mutation. This is different to what was previously observed with the I/D ACE polymorphism, for which a correlation between the DD genotype and FHC was found only in individuals carrying the Arg403 MYH7 mutation. More importantly, the distribution of CALM3 genotypes was different between affected and healthy carriers. Indeed, TT frequency was higher in affected carriers when compared with healthy carriers. This suggests that the 234T.A polymorphism is a potential modifier gene for FHC.
Calmodulin is a ubiquitous, highly conserved Ca 2þ sensor of 17 kDa involved in the regulation of a wide variety of cellular events. In humans, CaM is transcribed from three genes that encode identical amino acids, although the coding sequences of the three genes differ markedly in the nucleotide composition. Although CALM1 and CALM2 genes contain a classical regulatory element, a TATA box, 28 the 5 0 -flanking region of CALM3 has no TATA box but a typical feature of a house-keeping gene with a high GC content. 24, 29 The three CaM genes give rise to five different transcripts that are present in most of the tissues. In the rat heart, four isoforms are present, 30 but no complete study has been obtained in the human heart. The few studies performed in humans showed that CALM3 gene is five-fold more actively transcribed than the other two genes in proliferating teratoma cells, 25 proliferating activated T lymphocytes and several lymphoblastoid cell lines. 31, 32 The protein level of CaM was shown to decline several-fold in close temporal association with the declining population of proliferating rat cardiomyocytes. 33 These data suggest that the CALM3 gene may be specifically and differently regulated during cardiac cell proliferation and/or cardiac hypertrophy. The CALM3 gene polymorphism is located close to a conserved regulatory element, AGGGA, previously noted in promoters of other Ca 2þ -binding protein genes of higher vertebrates. Particularly, this element was found in promoters of the three human CaM genes, 24, 28, 34 chicken CaM gene, 35 human and rat parvalbumin genes, 36, 37 and in mouse and chicken myosin light chain lf/3f. 38, 39 It has been shown that this element is repeated and is a Ca 2þ -responsive element that regulates the expression of CALM2 and calbindin D28 genes in mouse Purkinje cells. 40 Because the CALM3 polymorphism is located close to this element, it could result in differential regulation of the transcription of the CALM3 gene.
In the present paper, we show that the CALM3 promoter containing the T allele exhibits lower activity compared with the promoter with the A allele in both HEK293 cells and NRCM. If these data were translatable to the human heart, patients with the T allele would be expected to have lower CALM3 mRNA levels. Unfortunately, this question cannot be directly addressed due to the lack of myocardial tissues of these patients. But it is interesting to note that reduced CALM3 mRNA levels have been observed in myocardial samples from patients with end-stage heart failure. 41 Interestingly, recent data indicate that CaM modifies the phenotype of Drosophila overexpressing human cMyBP-C. 42 How a decrease in the amount of CaM could affect the development of hypertrophy and/or dysfunction of the heart remains elusive at present. But given the essential role of Ca 2þ for virtually all aspects of electromechanical coupling, growth and energy metabolism (for reviews, see references 43 -45) , any changes in one of the central Ca 2þ -binding proteins are very likely to have multiple and important consequences. Studies are needed that specifically address this question, for example by knock-in the polymorphism in the CALM3 gene in mice.
In conclusion, the present study provides evidence that the 234T.A CALM3 polymorphism is a potential candidate to modulate the development of FHC. Further analyses are needed to correlate the CALM3 genotypes and CaM expression in myocardial tissue of patients with FHC. Conflict of interest: none declared.
